You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Innovative Methodologies for Manufacturing of Lethality Test Articles

    SBC: MATSYS INCORPORATED            Topic: MDA17T001

    The experimental validation of the DoDs weapon systems is at the cornerstone of national security considerations. The structural requirements for the targets utilized impose a severe cost and lead time burden due to the limitations imposed by the traditional manufacturing processes currently used. Novel manufacturing methods for metal alloys have been established in the past years, but they have y ...

    STTR Phase I 2018 Department of DefenseMissile Defense Agency
  2. Novel Structure-Preserving Algorithms for Accurate Rocket Trajectory Propagation

    SBC: OPTIMAL SYNTHESIS INC.            Topic: MDA17T002

    The Department of Defense uses large-scale high-resolution federated simulations to propagate rocket vehicle trajectories. Runge-Kutta methods have served as a de-facto standard while conducting such simulations. However, there are several challenges while using Runge-Kutta methods for this task. Firstly, there should be exact time-step matching between federates, otherwise the states have to be i ...

    STTR Phase I 2018 Department of DefenseMissile Defense Agency
  3. SmallSat Stirling Cryocooler for Missile Defense (SSC-X)

    SBC: WECOSO, INC.            Topic: MDA17T003

    West Coast Solutions (WCS), in collaboration with the Georgia Institute of Technology and Creare LLC, proposes an adaptation of our SmallSat Stirling Cryocooler (SSC) technology in response to STTR Topic MDA17-T003: High-Efficiency, Low-Volume, Space-Qualified Cryogenic-Coolers. In Phase 1 we will scale up a design currently in development for NASA to meet the Missile Defense Agency (MDA) topic re ...

    STTR Phase I 2018 Department of DefenseMissile Defense Agency
  4. Smallsat Cryocooler System

    SBC: IRIS TECHNOLOGY CORPORATION            Topic: MDA17T003

    The Iris Technology team which also include Northrop Grumman Aerospace Systems (NGAS) and the University of Wisconsin, is attacking the problem of high-efficiency, low-volume, space-qualified cryocooler systems.The team has a firm starting point by leveraging the Northrop Grumman Microcryocooler and the Iris Technology mLCCE (Miniature Low Cost Control Electronics).TMU enhancement will start with ...

    STTR Phase I 2018 Department of DefenseMissile Defense Agency
  5. Thin-Ply Composite Missile Structures

    SBC: MATERIALS RESEARCH & DESIGN INC            Topic: MDA17T004

    The Missile Defense Agency (MDA) has multiple system platforms to defeat an Intercontinental Ballistic Missile (ICBM).The MDAs solution for defeating a midcourse threat is the Ground-Based Midcourse Interceptor (GMI).The GMI is comprised of the Orbital Boost Vehicle (OBV) and an Exoatmospheric Kill Vehicle (EKV), developed by Orbital ATK and Raytheon respectively.The OBV carries the EKV to the ICB ...

    STTR Phase I 2018 Department of DefenseMissile Defense Agency
  6. Lightweight Structural Components of a Missile Body

    SBC: ALPHASTAR TECHNOLOGY SOLUTIONS LLC            Topic: MDA17T004

    The Ground-Based Interceptor (GBI) missile is the weapon component of the Ground-Based Midcourse Defense (GMD) system that consists of a rocket booster and kinetic kill vehicle. Recently, MDA has sought technologies to improve the performance of the booster vehicle (BV). To date, studies have shown that reductions in weight have a direct impact on overall effectiveness. The current proposal aims t ...

    STTR Phase I 2018 Department of DefenseMissile Defense Agency
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus

    SBC: EVRYS BIO LLC            Topic: CBD18A002

    In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government